Yi-hsin Liang

Hsin Chu Branch
Hsinchu, TNQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Conversion-intent definitive liver-directed therapy improves survival in liver-predominant metastatic colorectal cancer.

Conversion-intent definitive liver-directed therapy improves survival in liver-predominant metastatic colorectal cancer.

Journal: American journal of cancer research

Published: February 11, 2026

Optimizing third-line and beyond therapies for metastatic colorectal cancer in Taiwan: an evidence-based consensus.

Optimizing third-line and beyond therapies for metastatic colorectal cancer in Taiwan: an evidence-based consensus.

Journal: Therapeutic advances in medical oncology

Published: February 02, 2026

Epigenetic reprogramming of hexokinase domain containing 1 (HKDC1) promotes proliferation in colorectal cancer.

Epigenetic reprogramming of hexokinase domain containing 1 (HKDC1) promotes proliferation in colorectal cancer.

Journal: American journal of cancer research

Published: January 10, 2026

Managing Skin Side Effects Associated With Oncology Treatments: Asian Perspective on Use of Dermocosmetics.

Managing Skin Side Effects Associated With Oncology Treatments: Asian Perspective on Use of Dermocosmetics.

Journal: Asia-Pacific journal of clinical oncology

Published: January 07, 2026

Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial.

Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial.

Journal: Nature medicine

Published: September 27, 2025

Efficacy and safety of first-line cetuximab therapy for older patients (aged ≥ 70 years) with RAS wild-type metastatic colorectal cancer: a nationwide real-world study.

Efficacy and safety of first-line cetuximab therapy for older patients (aged ≥ 70 years) with RAS wild-type metastatic colorectal cancer: a nationwide real-world study.

Journal: American journal of cancer research

Published: June 04, 2025

Combination of anti-epidermal growth factor receptor antibodies plus trifluridine-tipiracil as rechallenge strategy improves treatment outcomes in patients with RAS/BRAF wild-type refractory metastatic colorectal cancer.

Combination of anti-epidermal growth factor receptor antibodies plus trifluridine-tipiracil as rechallenge strategy improves treatment outcomes in patients with RAS/BRAF wild-type refractory metastatic colorectal cancer.

Journal: American journal of cancer research

Published: May 30, 2025

A novel approach for quantifying therapeutic monoclonal antibodies in blood through liquid chromatography-tandem mass spectrometry.

A novel approach for quantifying therapeutic monoclonal antibodies in blood through liquid chromatography-tandem mass spectrometry.

Journal: Analytica chimica acta

Published: May 12, 2025

Metastatic Colon Cancer Recurring After Cetuximab Plus Doublet Chemotherapy Harboring Acquired KRAS G12C Mutant that Responded to Sotorasib Plus Cetuximab.

Metastatic Colon Cancer Recurring After Cetuximab Plus Doublet Chemotherapy Harboring Acquired KRAS G12C Mutant that Responded to Sotorasib Plus Cetuximab.

Journal: JCO precision oncology

Published: April 18, 2025

A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumors.

A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumors.

Journal: Investigational new drugs

Published: March 17, 2025

Outcomes of upfront primary tumor resection in patients with synchronous RAS wild-type metastatic colorectal cancer.

Outcomes of upfront primary tumor resection in patients with synchronous RAS wild-type metastatic colorectal cancer.

Journal: American journal of cancer research

Published: October 07, 2024

Continuing anti-EGFR monoclonal antibody after secondary resection significantly prolongs overall survival for patients with metastatic colorectal cancer who were responsive to first-line anti-EGFR monoclonal antibody plus chemotherapy doublet.

Continuing anti-EGFR monoclonal antibody after secondary resection significantly prolongs overall survival for patients with metastatic colorectal cancer who were responsive to first-line anti-EGFR monoclonal antibody plus chemotherapy doublet.

Journal: American journal of cancer research

Published: September 16, 2024

Showing 1-12 of 31

Last Updated: 09/26/2026